Deliver the StealthX™ vaccine candidate to NIAID
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 7 Aug 2024
- Due
- 31 Dec 2024
- Delivered
- by 18 Aug 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“plans to deliver it to NIAID by the end of 2024”
What we found
Evidence strength A What the grades mean
Capricor delivered StealthX vaccine to NIAID for clinical trial initiation, but 8 months late; announced Q1 2025 delivery revision in November 2024.
-
A Capricor 8-K Filing October 16, 2024
“Currently, our vaccine candidate is in the manufacturing phase with plans to deliver it to NIAID by the end of 2024.” ✓ confirmed on the page
-
A Capricor 10-K Filing December 31, 2024
“manufacturing is underway for our StealthX™ vaccine and we have submitted an Investigational New Drug Application” ✓ confirmed on the page
-
B Capricor Announces First Subjects Dosed in Phase 1 Clinical Trial
“Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine” ✓ confirmed on the page
-
C Capricor Q3 2024 Financial Results and Corporate Update
“Currently, manufacturing is underway for our StealthX™ vaccine with current plans to deliver it to NIAID in the first quarter of 2025.” ✓ confirmed on the page
Checked 7 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +90 days
- 2 versions
-
Version 1 · original · stated 7 Aug 2024
Deadline 31 Dec 2024 (“by the end of 2024”) · wording expected
-
Version 2 · stated 13 Nov 2024
Deadline 31 Mar 2025 (“in the first quarter of 2025”) · wording expected
“current plans to deliver it to NIAID in the first quarter of 2025”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Delivery
- Indicative materiality
- Medium rules
- Action
- Deliver
- Deliverable
- StealthX™ vaccine candidate
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Capricor Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-CAPR-002550 · Corrections policy